jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Company profile
Ticker
JAGX
Exchange
Website
CEO
Lisa Conte
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Jaguar Animal Health, Inc.
SEC CIK
Corporate docs
Subsidiaries
Napo Pharmaceuticals, Inc. ...
JAGX stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
14 May 24
PRE 14A
Preliminary proxy
10 May 24
EFFECT
Notice of effectiveness
2 May 24
424B3
Prospectus supplement
1 May 24
S-3
Shelf registration
22 Apr 24
10-K/A
2023 FY
Annual report (amended)
17 Apr 24
8-K
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
9 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
S-8
Registration of securities for employees
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
Transcripts
JAGX
Earnings call transcript
2024 Q1
14 May 24
JAGX
Earnings call transcript
2023 Q4
1 Apr 24
JAGX
Earnings call transcript
2023 Q3
14 Nov 23
JAGX
Earnings call transcript
2023 Q2
14 Aug 23
JAGX
Earnings call transcript
2023 Q2
14 Aug 23
JAGX
Earnings call transcript
2023 Q1
15 May 23
JAGX
Earnings call transcript
2022 Q4
27 Mar 23
JAGX
Earnings call transcript
2022 Q3
14 Nov 22
JAGX
Earnings call transcript
2022 Q2
22 Aug 22
JAGX
Earnings call transcript
2022 Q1
10 May 22
Latest ownership filings
4
Pravin R Chaturvedi
17 Apr 24
4
Jonathan S. Wolin
17 Apr 24
4
Carol R. Lizak
17 Apr 24
4
Steven R. King
17 Apr 24
4
LISA A CONTE
17 Apr 24
SC 13G
Iliad Research & Trading, L.P.
29 Dec 23
4
Anula Jayasuriya
14 Aug 23
4
Jonathan B. Siegel
14 Aug 23
4
JOHN MICEK
14 Aug 23
4
JAMES J BOCHNOWSKI
14 Aug 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.67 mm | 11.67 mm | 11.67 mm | 11.67 mm | 11.67 mm | 11.67 mm |
Cash burn (monthly) | (no burn) | 224.67 k | 3.12 mm | 3.31 mm | 2.35 mm | 2.53 mm |
Cash used (since last report) | n/a | 356.18 k | 4.95 mm | 5.25 mm | 3.72 mm | 4.01 mm |
Cash remaining | n/a | 11.31 mm | 6.72 mm | 6.42 mm | 7.95 mm | 7.66 mm |
Runway (months of cash) | n/a | 50.4 | 2.2 | 1.9 | 3.4 | 3.0 |
Institutional ownership, Q4 2023
16.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 15 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 3.15 bn |
Total shares | 48.98 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Nantucket Investments | 23.63 mm | $3.15 bn |
Streeterville Capital | 11.50 mm | $0.00 |
Iliad Research & Trading | 4.88 mm | $0.00 |
Oasis Capital | 4.60 mm | $0.00 |
Mailman Joshua | 4.37 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Conte Lisa A | Common Stock | Option exercise | Acquire M | No | No | 0 | 600 | 0.00 | 4,600 |
5 Apr 24 | Conte Lisa A | RSU Common Stock | Grant | Dispose A | No | No | 0 | 600 | 0.00 | 0 |
5 Apr 24 | Lizak Carol R. | Common Stock | Option exercise | Acquire M | No | No | 0 | 60 | 0.00 | 611 |
5 Apr 24 | Lizak Carol R. | RSU Common Stock | Grant | Dispose A | No | No | 0 | 60 | 0.00 | 0 |
5 Apr 24 | Wolin Jonathan S. | Common Stock | Option exercise | Acquire M | No | No | 0 | 89 | 0.00 | 1,141 |
5 Apr 24 | Wolin Jonathan S. | RSU Common Stock | Grant | Dispose A | No | No | 0 | 89 | 0.00 | 0 |
5 Apr 24 | King Steven R. | Common Stock | Option exercise | Acquire M | No | No | 0 | 178 | 0.00 | 1,144 |
5 Apr 24 | King Steven R. | RSU Common Stock | Grant | Dispose A | No | No | 0 | 178 | 0.00 | 0 |
5 Apr 24 | Pravin R Chaturvedi | Common Stock | Option exercise | Acquire M | No | No | 0 | 134 | 0.00 | 1,270 |
5 Apr 24 | Pravin R Chaturvedi | RSU Common Stock | Grant | Dispose A | No | No | 0 | 134 | 0.00 | 0 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
17 May 24
Peering Into Jaguar Health's Recent Short Interest
9 May 24
Jaguar Health Announces Submission Of Clinical Trial Applications For Crofelemer To Treat Rare Disease Indications Microvillus Inclusion Disease And Short Bowel Syndrome In Europe
9 May 24
FDA Conditionally Approves Jaguar Health's Prescription Drug Crofelemer For Chemotherapy-Induced Diarrhea In Dogs
6 May 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
3 May 24
Press releases
Jaguar Health, Inc. Announces Reverse Stock Split
17 May 24
Jaguar Health Reports First Quarter 2024 Financial Results
14 May 24
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
13 May 24
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
9 May 24
Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
8 May 24